Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1963 1
1964 1
1967 2
1968 2
1969 2
1970 8
1971 148
1972 278
1973 104
1974 102
1975 69
1976 60
1977 68
1978 55
1979 61
1980 43
1981 57
1982 48
1983 56
1984 47
1985 66
1986 57
1987 49
1988 66
1989 76
1990 66
1991 74
1992 76
1993 73
1994 78
1995 64
1996 76
1997 84
1998 65
1999 49
2000 52
2001 57
2002 65
2003 80
2004 94
2005 121
2006 137
2007 161
2008 216
2009 300
2010 332
2011 326
2012 326
2013 297
2014 276
2015 257
2016 268
2017 303
2018 352
2019 225
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

5,932 results
Results by year
Filters applied: . Clear all
Page 1
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Soria JC, et al. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18. N Engl J Med. 2018. PMID: 29151359 Free article. Clinical Trial.
Third generation EGFR TKIs: current data and future directions.
Tan CS, Kumarakulasinghe NB, Huang YQ, Ang YLE, Choo JR, Goh BC, Soo RA. Tan CS, et al. Mol Cancer. 2018 Feb 19;17(1):29. doi: 10.1186/s12943-018-0778-0. Mol Cancer. 2018. PMID: 29455654 Free PMC article. Review.
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA. Oxnard GR, et al. Version 2. JAMA Oncol. 2018 Nov 1;4(11):1527-1534. doi: 10.1001/jamaoncol.2018.2969. JAMA Oncol. 2018. PMID: 30073261 Free PMC article.
Pyrotinib: First Global Approval.
Blair HA. Blair HA. Drugs. 2018 Nov;78(16):1751-1755. doi: 10.1007/s40265-018-0997-0. Drugs. 2018. PMID: 30341682 Review.
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.
Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN Jr, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV. Le X, et al. Clin Cancer Res. 2018 Dec 15;24(24):6195-6203. doi: 10.1158/1078-0432.CCR-18-1542. Epub 2018 Sep 18. Clin Cancer Res. 2018. PMID: 30228210 Free PMC article.
5,932 results
Jump to page
Feedback